Monday, January 8

6:00 p.m.–8:00 p.m.  WELCOME REMARKS AND OPENING KEYNOTE SESSION
Legends 1-4
Fred Hirsch, CEO, IASLC

6:10 p.m.–6:40 p.m.  Checkpoint blockade: “The good, bad, and the ugly”
Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY

6:40 p.m.–7:10 p.m.  The role of aneuploidy during tumorigenesis
Teresa Davoli, Harvard Medical School, Boston, MA

7:10 p.m.–7:40 p.m.  Functional lung cancer genomics through in vivo genome editing
Monte M. Winslow, Stanford University School of Medicine, Stanford, CA

7:40 p.m.–8:00 p.m.  Keynote discussion

8:00 p.m.–10:00 p.m.  OPENING RECEPTION
The Edge

Tuesday, January 9

7:00 a.m.–8:00 a.m.  CONTINENTAL BREAKFAST
The Edge

8:00 a.m.–10:00 a.m.  PLENARY SESSION 1: EARLY STEPS IN LUNG ONCOGENESIS
Legends 1-4

8:00 a.m.–8:25 a.m.  Elucidating lung stem cells and the initiation of lung cancer at single-cell resolution
Mark A. Krasnow, Stanford University, Stanford, CA

8:25 a.m.–8:50 a.m.  Early steps in lung oncogenesis
Samuel Janes, University College London, London, United Kingdom

8:50 a.m.–9:15 a.m.  Molecular mechanisms of lung cancer development: Between metabolic reprogramming and genomic instability in the field of cancerization
Pierre P. Massion, Vanderbilt University Medical Center, Nashville, TN

9:15 a.m.–9:40 a.m.  Influence of cancer initiation on tumor progression in SCLC
Julien Sage, Stanford University School of Medicine, Stanford, CA

9:40 a.m.–9:55 a.m.  Modeling Rb loss and pathway reactivation in lung adenocarcinoma*
David M. Feldser, University of Pennsylvania, Philadelphia, PA

10:00 a.m.–10:30 a.m.  BREAK
Abbey Road

10:30 a.m.–12:25 p.m.  PLENARY SESSION 2: EARLY DETECTION
Legends 1-4

10:30 a.m.–10:55 a.m.  Individualized risk-based lung cancer screening: The way forward
Christine D. Berg, National Cancer Institute, Bethesda, MD

10:55 a.m.–11:20 a.m.  Inflammation and immunity in pulmonary premalignancy
Steven M. Dubinett, David Geffen School of Medicine at UCLA, Los Angeles, CA

*Short talk from proffered abstract
CONFERENCE PROGRAM

11:20 a.m.–11:45 a.m.  
**Title to be announced**  
Avrum E. Spira, Boston University School of Medicine, Boston, MA

11:45 a.m.–12:10 p.m.  
**Gene networks, airway smoke injury, and cancer risk**  
Bruce A.J. Ponder, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom

12:10 p.m.–12:25 p.m.  
**Diagnostic and prognostic utility of urinary creatine riboside for early-stage non-small cell lung cancer***  
Takahiro Oike, National Cancer Institute, Bethesda, MD

12:25 p.m. – 12:35 p.m.  
POSTER SESSION A HIGHLIGHTS
(legends 1–4)  
*(not CME accredited)*

(A01)  
**Stem cell signals in the initiation and progression of non-small cell lung cancer**  
Alison G. Barber, University of California San Diego School of Medicine, San Diego, CA

(A02)  
**Oncogenic drivers of lung cancer induce production of CCL5 and recruitment of regulatory T cells**  
Elizabeth Franks, British Columbia Cancer Research Centre, Vancouver, BC, Canada

(A03)  
**Reversion of EMT sensitizes KRAS mutant cancers to MEK inhibition**  
David H. Peng, The University of Texas MD Anderson Cancer Center, Houston, TX

(A04)  
**Altered expression of IncRNAs overlapping pseudogene loci as an alternative mechanism of cancer gene regulation**  
Greg L. Stewart, British Columbia Cancer Research Centre, Vancouver, BC, Canada

12:40 p.m.–2:00 p.m.  
POSTER SESSION A AND LUNCH
(legends 5–6 and Encore)

2:30 p.m.–3:45 p.m.  
PLENARY SESSION 3: LIQUID BIOPSIES
(legends 1–4)

2:30 p.m.–2:55 p.m.  
**Early detection of molecular residual disease in localized lung cancer via circulating tumor DNA profiling**  
Maximilian Diehn, Stanford University, Stanford, CA

2:55 p.m.–3:20 p.m.  
**Circulating tumor DNA in early-stage NSCLC: A lung TRACERx study**  
Christopher Abbosh, University College London Cancer Institute, London, United Kingdom

3:20 p.m.–3:45 p.m.  
**ctDNA assessment of resistance and heterogeneity in EGFR mutant lung cancers**  
Zofia Piotrowska, Partners Cancer Care/MGH Cancer Center, Boston, MA

3:45 p.m.–4:00 p.m.  
BREAK  
Abbey Road

4:00 p.m.–6:15 p.m.  
PLENARY SESSION 4: HETEROGENEITY AND EVOLUTION
(legends 1–4)

4:00 p.m.–4:25 p.m.  
**Liquid biopsies and lung cancer evolution**  
Trever G. Bivona, University of California San Francisco, San Francisco, CA

4:25 p.m.–4:50 p.m.  
**Tracking Lung Cancer Evolution through therapy (TRACERx): Immune evasion, progression, and adaptation**  
Charles Swanton, The Francis Crick Institute and University College London Cancer Institute, London, United Kingdom

*Short talk from proffered abstract*
4:50 p.m.–5:15 p.m.  
**Evolution of acquired resistance in EGFR-mutant NSCLC**  
Aaron N. Hata, Massachusetts General Hospital, Charlestown, MA

5:15 p.m.–5:40 p.m.  
**Cell-of-origin footprints in lung cancer genomes and transcriptomes**  
Marcin Imielski, Weill Cornell Medical College, New York, NY

5:40 p.m.–5:55 p.m.  
**Dissecting the playbook of cancer: Genomic analysis of 100,000 human tumors reveals elaborate patterns of activation of the RTK-RAS-MAPK pathway**  
Gerard Manning, Genentech, South San Francisco, CA

5:55 p.m.–6:10 p.m.  
**Decoding tumor microenvironment to enhance NSCLC targeted therapy**  
Haichuan Hu, MGH Cancer Center/Harvard Medical School, Charlestown, MA

---

**Wednesday, January 10**

7:00 a.m.–8:00 a.m.  
CONTINENTAL BREAKFAST  
The Edge

8:00 a.m.–10:00 a.m.  
PLENARY SESSION 5: IMMUNOTHERAPY: BIOMARKERS AND CHECKPOINT BLOCKADE  
Legends 1-4

8:00 a.m.–8:25 a.m.  
**Immunotherapy: Biomarkers and checkpoint blockade in NSCLC**  
David P. Carbone, The Ohio State University Comprehensive Cancer Center, Columbus, OH

8:25 a.m.–8:50 a.m.  
**Mechanisms of acquired resistance to immune checkpoint inhibitors in lung cancer**  
Katerina A. Polit, Yale University Cancer Center, New Haven, CT

8:50 a.m.–9:15 a.m.  
**Immunotherapy for thoracic malignancies beyond NSCLC**  
Solange Peters, Centre Cordonné d’Oncologie-CHUV, Lausanne, Switzerland

9:15 a.m.–9:30 a.m.  
**Safety and activity of the IL-15/sIL-15Rα complex ALT-803 in combination with the anti-PD1 mAb nivolumab in metastatic non-small cell lung cancer**  
John Wrangle, Medical University of South Carolina, Charleston, SC

9:30 a.m.–9:45 a.m.  
**Investigating ectopic lymphoid aggregates in a genetically engineered mouse model of lung adenocarcinoma**  
Kelli Connolly, Yale University, New Haven, CT

9:45 a.m.–10:00 a.m.  
**Role of the microbiota in inflammation and lung cancer**  
Ana I. Robles, National Cancer Institute, Bethesda, MD

10:00 a.m.–10:30 a.m.  
BREAK  
Abbey Road

10:30 a.m.–11:20 a.m.  
PLENARY SESSION 6: VACCINES, CELLULAR THERAPY, NEOANTIGEN TARGETING  
Legends 1-4

10:30 a.m.–10:55 a.m.  
**Allele-specific HLA loss and immune escape in lung cancer evolution**  
Rachel Rosenthal, University College London, London, United Kingdom

10:55 a.m.–11:20 a.m.  
**Are tumors predictable? Inherited immune variation constrains tumor evolution**  
Hannah K. Carter, University of California San Diego, San Diego, CA

11:30 a.m.–12:00 p.m.  
SPECIAL LECTURE  
Legends 1-4

11:30 a.m.–12:00 p.m.  
**Developing precision medicine–based new lung cancer therapeutics**  
John D. Minna, UT Southwestern Medical Center, Dallas, TX

*Short talk from proffered abstract*
CONFERENCE PROGRAM

12:00 p.m.–1:30 p.m.  LUNCH ON OWN

1:30 p.m.–3:40 p.m.  PLENARY SESSION 7: SMALL CELL LUNG CANCER
Legends 1-4

1:30 p.m.–1:55 p.m.  Mechanisms of chemoresistance in SCLC
Charles M. Rudin, Memorial Sloan Kettering Cancer Center, New York, NY

1:55 p.m.–2:20 p.m.  MYC drives molecular and therapeutically distinct subtype of SCLC
Trudy G. Oliver, University of Utah Huntsman Cancer Institute, Salt Lake City, UT

2:20 p.m.–2:45 p.m.  The genomic landscape of SCLC and other neuroendocrine lung tumors
Julie George, University of Cologne, Cologne, Germany

2:45 p.m.–3:10 p.m.  Circulating Tumor Cells: A liquid biopsy for SCLC with multiple applications
Caroline Dive, Cancer Research UK Manchester Institute, Manchester, United Kingdom

3:10 p.m.–3:25 p.m.  Functional characterization and evolutionary reconstruction of small cell lung cancer transformation of EGFR-mutant lung adenocarcinomas*
June-Koo Lee, Harvard Medical School, Boston, MA

3:25 p.m.–3:40 p.m.  Alterations in cell junctions and neuroendocrine differentiation are key early steps in Crebbp/Ep300 mutation-driven SCLC development*
Kwon-Sik Park, University of Virginia, Charlottesville, VA

3:40 p.m.–4:00 p.m.  BREAK
Abbey Road

4:00 p.m.–5:30 p.m.  PLENARY SESSION 8: IMAGING, RADIATION ONCOLOGY, RADIOMICS
Legends 1-4

4:00 p.m.–4:25 p.m.  ImmunoPET imaging of DLL3 in small cell lung cancer
John T. Poirier, Memorial Sloan Kettering Cancer Center, New York, NY

4:25 p.m.–4:50 p.m.  Radiation therapy in lung cancer: Recent trends and future directions
Daniel R. Gomez, The University of Texas MD Anderson Cancer Center, Houston, TX

4:50 p.m.–5:15 p.m.  Multiscale modeling of lung cancer
Olivier Gevaert, Stanford University, Stanford, CA

5:15 p.m.–5:30 p.m.  Multimodality imaging of human lung squamous cell carcinoma reveals unique metabolic dependencies that are effectively targeted with metabolic-based therapies*
David B. Shackelford, David Geffen School of Medicine at UCLA, Los Angeles, CA

5:30 p.m.–5:40 p.m.  POSTER SESSION B HIGHLIGHTS
Legends 1-4
(not CME accredited)

(B01)  BLU-667: A highly selective RET inhibitor to target RET-driven NSCLC
Erica K. Evans, Blueprint Medicines, Cambridge, MA

(B02)  Heterogeneity of epithelial-to-mesenchymal transition and resistance mutation in ALK inhibitor-resistant lung cancer and its circumvention
Koji Fukuda, Cancer Research Institute, Kanazawa University, Kanazawa, Japan

(B03)  Suppression of lung adenocarcinoma growth and metastasis by stromal Hedgehog pathway activation
James Kim, UT Southwestern Medical Center, Dallas, TX

5:40 p.m.–7:00 p.m.  POSTER SESSION B AND RECEPTION
Legends 5-6 and Encore

*Short talk from proffered abstract

16  LUNG CANCER TRANSLATIONAL SCIENCE FROM THE BENCH TO THE CLINIC
Thursday, January 11

7:00 a.m.–8:00 a.m.  CONTINENTAL BREAKFAST
The Edge

8:00 a.m.–10:00 a.m.  PLENARY SESSION 9: TUMOR MICROENVIRONMENT
Legends 1-4
8:00 a.m.–8:25 a.m.  Comprehensive enumeration of immune cells in the tumor microenvironment using multiplexed ion beam imaging
Michael Angelo, Stanford University School of Medicine, Stanford, CA
8:25 a.m.–8:50 a.m.  Targeting cellular heterogeneity in lung adenocarcinoma
Tuomas Tammela, Memorial Sloan Kettering Cancer Center, New York, NY
8:50 a.m.–9:15 a.m.  Immune contexture evolution during lung cancer carcinogenesis and its potential clinical implications
Jianjun Zhang, The University of Texas MD Anderson Cancer Center, Houston, TX
9:15 a.m.–9:40 a.m.  Regulatory T cells, polymorphisms, and response to checkpoint blockade: From mechanisms to potential biomarkers
Sergio Quezada, University College London Cancer Institute, London, United Kingdom
9:40 a.m.–9:55 a.m.  Hyperspectral imaging tools capture the spatial organization of cell subsets within the tumor microenvironment*
Katey S.S. Enfield, British Columbia Cancer Research Centre, Vancouver, BC, Canada

10:00 a.m.–10:15 a.m.  BREAK
Abbey Road

10:15 a.m.–12:00 p.m.  PLENARY SESSION 10: TARGETED THERAPIES AND ONCOGENIC SIGNALING
Legends 1-4
10:15 a.m.–10:40 a.m.  Title to be announced
Neal Rosen, Memorial Sloan Kettering Cancer Center, New York, NY
10:40 a.m.–10:55 a.m.  A combined protein-protein interaction and genetic interaction map defines new and critical Kras effectors in non-small cell lung cancer*
Peter K. Jackson, Stanford University School of Medicine, Stanford, CA
10:55 a.m.–11:20 a.m.  Progress and unanswered questions in EGFR mutation-positive lung cancer
Lecia Sequist, Massachusetts General Hospital, Boston, MA
11:20 a.m.–11:35 a.m.  MET copy number gain is associated with gefitinib resistance in leptomeningeal carcinomatosis of EGFR-mutant lung cancer*
Shigeki Nanjo, University of California San Francisco, San Francisco, CA
11:35 a.m.–12:00 p.m.  The art in the science of ALK-positive lung cancer management
Tony S.K. Mok, Chinese University of Hong Kong, Shatin, Hong Kong

*Short talk from proffered abstract